Share-based Payment Arrangement, Expense of Vincerx Pharma, Inc. from 31 Dec 2020 to 31 Mar 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Vincerx Pharma, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2020 to 31 Mar 2025.
  • Vincerx Pharma, Inc. Share-based Payment Arrangement, Expense for the quarter ending 31 Mar 2025 was $435,000, a 18% decline year-over-year.
  • Vincerx Pharma, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 31 Mar 2025 was $3,380,000, a 25% increase year-over-year.
  • Vincerx Pharma, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $3,473,000, a 2.5% decline from 2023.
  • Vincerx Pharma, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $3,563,000, a 65% decline from 2022.
  • Vincerx Pharma, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $10,056,000, a 57% decline from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Vincerx Pharma, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2025 $3,380,000 $435,000 -$93,000 -18% 01 Jan 2025 31 Mar 2025 10-Q 15 May 2025 2025 Q1
Q4 2024 $3,473,000 $610,000 +$153,000 +33% 01 Oct 2024 31 Dec 2024 10-K 27 Mar 2025 2024 FY
Q3 2024 $3,320,000 $1,423,000 +$794,000 +126% 01 Jul 2024 30 Sep 2024 10-Q 12 Nov 2024 2024 Q3
Q2 2024 $2,526,000 $912,000 -$181,000 -17% 01 Apr 2024 30 Jun 2024 10-Q 08 Aug 2024 2024 Q2
Q1 2024 $2,707,000 $528,000 -$856,000 -62% 01 Jan 2024 31 Mar 2024 10-Q 15 May 2025 2025 Q1
Q4 2023 $3,563,000 $457,000 +$1,311,000 01 Oct 2023 31 Dec 2023 10-K 27 Mar 2025 2024 FY
Q3 2023 $2,252,000 $629,000 -$1,661,000 -73% 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024 2024 Q3
Q2 2023 $3,913,000 $1,093,000 -$2,269,000 -67% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 $6,182,000 $1,384,000 -$3,874,000 -74% 01 Jan 2023 31 Mar 2023 10-Q 14 May 2024 2024 Q1
Q4 2022 $10,056,000 $854,000 -$6,740,000 -115% 01 Oct 2022 31 Dec 2022 10-K 29 Mar 2024 2023 FY
Q3 2022 $16,796,000 $2,290,000 -$3,785,000 -62% 01 Jul 2022 30 Sep 2022 10-Q 14 Nov 2023 2023 Q3
Q2 2022 $20,581,000 $3,362,000 -$3,275,000 -49% 01 Apr 2022 30 Jun 2022 10-Q 07 Aug 2023 2023 Q2
Q1 2022 $23,856,000 $5,258,000 +$543,000 +12% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1
Q4 2021 $23,313,000 $5,886,000 01 Oct 2021 31 Dec 2021 10-K 28 Mar 2023 2022 FY
Q3 2021 $6,075,000 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2022 2022 Q3
Q2 2021 $6,637,000 01 Apr 2021 30 Jun 2021 10-Q 11 Aug 2022 2022 Q2
Q1 2021 $4,715,000 01 Jan 2021 31 Mar 2021 10-Q 12 May 2022 2022 Q1

Vincerx Pharma, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $3,473,000 -$90,000 -2.5% 01 Jan 2024 31 Dec 2024 10-K 27 Mar 2025 2024 FY
2023 $3,563,000 -$6,493,000 -65% 01 Jan 2023 31 Dec 2023 10-K 27 Mar 2025 2024 FY
2022 $10,056,000 -$13,257,000 -57% 01 Jan 2022 31 Dec 2022 10-K 29 Mar 2024 2023 FY
2021 $23,313,000 +$18,931,000 +432% 01 Jan 2021 31 Dec 2021 10-K 28 Mar 2023 2022 FY
2020 $4,382,000 01 Jan 2020 31 Dec 2020 10-K 29 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.